Target populations for early diagnosis, disease course prediction and interventions in Alzheimer’s disease are a major focus of current research. Subjective cognitive decline (SCD) has emerged as a pre-mild cognitive impairment (pre-MCI) at risk condition of dementia and cognitive decline.
Initial studies provide evidence for an enrichment of AD pathology, particularly in memory clinic populations. Furthermore, there is evidence that biomarker evidence of AD pathology predict decline. The recent National Institute on Aging (NIA-AA) Alzheimer’s Association research criteria have linked SCD with the transitional stage 2 of AD, which reflect the initial pre-MCI symptomatic phase of the disease.
Despite these highly promising first steps, SCD is still a new concept and numerous questions remain. The journal of Alzheimer’s disease and therapy address to emerging by topic by presenting a series of papers on SCD with new research of several of the leading groups in the field.
Guest Editors: José Luis Molinuevo, Frank Jessen & Wiesje Van der Flier
This series will be publishing manuscripts throughout the year.